chidamide + camrelizumab

Chidamide + camrelizumab is a combination therapy that pairs two distinct mechanisms of action to treat cancer. Chidamide (also known as tucidinostat) is a subtype-selective histone deacetylase (HDAC) inhibitor that targets Class I HDAC1, HDAC2, HDAC3, and Class IIb HDAC10[7]. Camrelizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor[6]. The combination works by: 1. Chidamide modifying histone acetylation, affecting gene expression related to cell cycle, differentiation, and apoptosis 2. Camrelizumab blocking the PD-1 pathway, preventing tumor cells from evading immune surveillance 3. Together, they synergistically enhance T-cell chemokine expression, augment the interferon-gamma response, and increase CD8 T-cell infiltration in the tumor microenvironment[5] This combination has shown particular promise in treating relapsed or refractory classical Hodgkin lymphoma (cHL) and other hematological malignancies.

Other names

Chidamide + anti-PD-1tucidinostat + camrelizumab